Yixi Bio Advances Global HMO Industrialization with Strategic Expansions and World's Largest Production Facility

In the golden autumn of September, Suzhou Yixi Biotechnology Co., Ltd. and its subsidiary Tongxi Biotechnology actively expanded into multiple important domestic and international exhibitions and cooperation projects, vigorously promoting the industrialization process of HMO (Human Milk Oligosaccharides).

Suzhou Yixi Biotechnology Co., Ltd. Made a Significant Appearance in the Core Southeast Asian Market, Showcasing Multiple HMO Innovative Application Solutions. At the booth, food and beverage manufacturers and brand representatives from around the world gathered continuously to engage in in-depth discussions on the technical applications and market prospects of HMOs in specific categories. This successfully expanded the potential international cooperation network, laying a solid foundation for entering the Asia-Pacific market.

Suzhou Yixi Biotechnology Co., Ltd.'s HMO production factory in Huangshan, with an annual output of 3,000 tons, has successfully completed its structural topping-out. Once fully constructed, it will become the world's largest HMO factory. This marks Yixi Biotechnology's transition from technological leadership to absolute capacity dominance, representing a decisive breakthrough in the global large-scale production capability of HMO.

Suzhou Yixi Biotechnology Co., Ltd., a representative company in the field of synthetic biology, was invited to participate in the exhibition. Wang Yan, Director of the Huangshan Municipal Industry and Information Technology Bureau, visited the booth in person to listen to the report. A specially customized HMO intelligent factory miniature dynamic model created by Suzhou Yixi Biotechnology vividly presented the complex bio-fermentation process in an intuitive and engaging way, becoming one of the highlights of the exhibition.

This month, the synthetic biology industry witnessed a landmark event. BioMap, the global pioneer in foundational large models for life sciences, and Suzhou Yixi Biotechnology Co., Ltd., China's first company to achieve industrialization of HMO (Human Milk Oligosaccharides), officially announced a strategic partnership under the witness of the Huangshan District Party Committee and Government. Moving forward, the two parties will engage in in-depth cooperation to address bottlenecks in the synthetic biology industry.

Suzhou Yixi Biotechnology Co., Ltd. Invited to Participate in Anhui Province Harvest Festival, Showcasing HMO Raw Materials and HMO-Added Health Foods at the Event. Allowing More Consumers to Directly Experience the Practical Application of Synthetic Biotechnology in Traditional Agricultural Products.

At the end of September, Suzhou Yixi Biotechnology Co., Ltd. was invited to participate in the third annual meeting of the National Dairy Technology Innovation Center. At this exhibition, Yixi Biotechnology showcased comprehensive solutions ranging from HMO to feed microbial proteins. The company engaged in in-depth exchanges with industry experts and leading dairy brands, further solidifying its key position in the core supply chain of the dairy industry.